Publications by authors named "P Pizzutillo"
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
Transl Lung Cancer Res
August 2020
The identification of prognostic and predictive biomarkers for high-programmed cell death-ligand 1 (PD-L1) advanced non-small cell lung cancer (aNSCLC) treated with first-line pembrolizumab could support the decision-making about possible combination therapies. To explore the baseline neutrophil-to-lymphocyte ratio (NLR) with the possible addition of PD-L1 tumour proportion score (TPS) level or lactate dehydrogenase (LDH) as possible prognostic biomarkers by a multicenter retrospective exploratory analysis aiming at identifying favourable-risk patients. Baseline NLR was available for all 132 high PD-L1 aNSCLC patients, PD-L1 level and LDH for 81 (61%) and 85 (64%) patients, respectively.
View Article and Find Full Text PDFPurpose: Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several drugs provided an impressive outcome benefit, the most effective sequential strategy is still unknown. We describe outcomes of real-life patients according to the treatment strategy received.
View Article and Find Full Text PDFArticle Synopsis
- Osimertinib is commonly used for T790M EGFR-positive NSCLC patients, but many experience progression that isn't amenable to further drug treatments, leading to exploration of alternative strategies like chemotherapy and local ablative treatments.
- A study of 144 patients found that those who continued osimertinib beyond disease progression had better outcomes than those who switched therapies or received best supportive care only, with longer progression-free and overall survival rates.
- The key takeaway is that extending osimertinib treatment, with or without local ablative treatments, is associated with improved patient outcomes compared to switching therapies or receiving supportive care alone.